• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA

    AGC Biologics Appoints Boulder Site GM

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling

    AbbVie Licenses ProBioGen’s GlymaxX Technology

    Improving Product Profitability
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Alcami

    Cytovance Biologics

    Aphena Pharma Solutions

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Cytovance Biologics

    Emergent BioSolutions

    Reed-Lane

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Drug Substances: Scale-Up Challenges

    A look at the necessary steps and evaluations needed in order to manage complexities and reduce timelines.

    Drug Substances: Scale-Up Challenges
    Related CONTENT
    • Vetio Animal Health
    • Recipharm
    • Covance Unveils New R&D Center in Shanghai
    • Contracting And Outsourcing Exhibitor List
    • Quality Metrics Feedback
    Anders Högdin, Senior Sales Director, Recipharm09.16.19
    When a drug candidate is identified, several challenges lie ahead. Initially, it is necessary to prove that the chosen molecule has the intended pharmacological effect. It is also vital that the safety of the molecule, as well as its therapeutic benefits, are demonstrated. Moreover, the drug developer needs to ensure that the drug substance can be manufactured at industrial scale at a quality that meets expectations.

    Drug substance is needed for a large number of safety studies and clinical trials. This poses many challenges for the chemist in terms of quantity and quality and there are many considerations with regards to safety and technical issues that must be taken into account. It is essential that the drug substance manufacturing process is scalable from a technical and economic viewpoint. Additionally, when progressing a drug substance from milligram to kilogram quantities, there are characteristics of the drug substance that can impact formulation.

    This article discusses the key challenges facing chemists during the scale-up process for drug substances and sheds light on the different factors that are key to the success of a project.

    From milligram method to multi kilogram process: scale-up challenges
    As a drug progresses from the candidate drug (CD) selection into, and through the clinical phases, increasingly more drug substance is required. As a result, a milligram preparative method must become a multi kg process, without impacting the quality or the performance of the active pharmaceutical ingredient (API). Put simply, there is an increasing demand for greater quantities, quality and documentation when moving from the pre-clinical phase towards market authorization.

    A substantial amount of expertise is required to seamlessly take products from pre-clinical to clinical and then to commercial scale. The routes of synthesis used by medicinal chemists is typically designed for diversity and speed in order to be able to make a lot of variations from an identified hit substance. In this phase the main objective is to improve and optimize the lead substance for its desired primary activity and its physicochemical properties required for later administering of the substance to patients. Thus, with this focus it is not uncommon that the synthetic routes chosen at this stage tend to lack optimal performance with regards to parameters such as economy, safety and robustness; parameters which become increasingly important when performed at a larger scale. As a result, there is a strong likelihood that a synthesis proven within a lab environment will be unsuccessful, or at least unsuitable, when transferred into a production environment.

    The time required for the complete process of moving a substance from pre-clinical into early phase clinical development can vary greatly and depends on the length—number of chemical transformations—and complexity of the synthesis. It is important to realize however that the development of a robust process may also be considered as a stepwise process, where development and delivery of the first kilogram for phase I will not have all the characteristics of the final commercial multi kilogram (or ton) manufacturing process. Therefore, typical project and development times will vary greatly, also depending on the ambition, taking anything from a few months to a year, or more. In order to meet intended, and often very short, timescales for early phase API deliveries, it is important to identify the key parameters for successful scale-up and try to predict any problems that may arise as early as possible. These parameters will vary between projects and there are several aspects to consider during API scale-up and transfer to drug product development, described below.

    Route scouting
    During the early phases, chemists must typically produce from around a few hundred grams of drug substance for safety studies to a few kilograms for first-in-human studies. While there is usually time available to improve the manufacturing process before commercial manufacture, this is the period in which chemists should consider any future actions as making changes may be more difficult or more expensive at a later date. This is because the selected manufacturing process has the potential to affect the purity profile which can subsequently impact the credibility of the safety studies, analytical methods and carryovers.

    Route scouting is integral to identifying a practical, safe and cost-effective process for the synthesis of a compound on a large scale. During this process, chemists must determine the scalability of the existing medicinal chemistry route and see if there are any other suitable alternative routes.

    The following are examples of questions that should be asked during the route scouting process:
    • Is the process safe to scale up?
    • Are the raw materials available on a larger scale?
    • Are they affordable?
    • Are there any technology restrictions with the existing route? High pressure reactions Extreme high or low temperature requirements?
    • Are there any valid patents on reagents or process steps that we need to consider?
    • Are there any solid intermediates? How are they isolated and purified?
    • How is the API isolated and purified?
    • Are there any environmental aspects to consider?
    In order to evaluate any other promising routes to the target, a thorough review of existing literature is usually carried out during this stage. Often there is a focus on finding ways that will help to reduce the number of synthetic steps to shorten production times to provide a cost-effective and timely delivery. Embedded in this thought process lies all of the above parameters. In addition, the routes finally chosen for further synthetic evaluation and process development may not always be the shortest but are instead dictated by other factors; raw material cost and availability, technology, safety, etc.

    Additionally, a greater number of synthetic steps may sometimes be required to ensure that there are enough GMP steps within the process to meet regulatory requirements. Starting material selection is one of the primary regulatory topics being discussed across the pharmaceutical industry currently. At the start of a project, correct regulatory starting material (RSM) is essential in order to prevent starting material redefinition. Material redefinition is a costly and time-consuming process which can often result in complete process remodeling.

    Although not necessarily part of the route scouting process as such, the solid-state properties and characteristics of the final API is an extremely important aspect to take into consideration at an early stage, and especially so if the API is intended for solid dosage forms. The solid-state properties of the API will influence important factors such as stability, solubility, formulation and process robustness. A careful evaluation and selection of a proper salt form and polymorph at an early stage is therefore strongly recommended.   
     
    Collaboration
    When scaling a drug substance, effective collaboration is a necessity. With various experts such as process chemists and analytical chemists involved in the development of the drug substance, but also formulation scientists in the interface and transfer into drug product development, a clear chain of communication is crucial to the success of a project. Cross-functional collaboration enables the team to work with a clear and common goal; thus, meeting clinical plans and strict timeframes. This collaboration includes both transfer of knowledge but also actual test batch material for hands-on laboratory work.

    The start date of clinical studies is an important aspect of the scale-up process. For example, it is important that the clinical trial material is manufactured in a timely manner, which also requires a timely supply of the GMP drug substance. The delivery of these materials is reliant upon effective collaboration. 

    An integrated approach
    Drug substance development and manufacturing should also consider the intended drug product in order to make the transition into drug product development as seamless as possible. As such, many drug developers are recognizing the benefits of working with contract development and manufacturing organizations (CDMOs) that have experience and knowledge in the development and manufacture of both drug substances and drug products.

    In addition, using a partner that understands the whole process, from the pre-clinical stage through to commercial manufacture, can help to reduce time and manage complexity. Furthermore, amongst several other benefits, CDMOs with a comprehensive offering tend to have multi-purpose plants which allows the manufacture of several drug substances, at one time. Thus, their facilities are usually equipped for diversity in order to effectively react to different needs. In addition, and perhaps more importantly, CDMOs offering a variety of batch sizes can also accommodate seamless transfer of the project into larger vessels as the project progresses through the clinical phases. As a result of this flexibility, challenges and timelines can be overcome more efficiently. 

    Conclusion
    There are several challenges involved in the scale-up process of a drug substance. As such, it is important to ensure that the necessary steps and evaluations are carried out in order to manage complexities and reduce timelines. Taking an integrated approach to drug substance and drug product development can help to overcome issues and speed up timelines. As such, the popularity of working with CDMOs that offer end-to-end solutions and that can develop drug substances with the end goal in mind is increasing. 


    Anders Högdin is senior sales director at Recipharm. He joined Recipharm in 2015 to head the business development and sales team within development services in Europe. With a wealth of experience in early process development of drug substance working within the CDMO industry, he also holds an MSc in chemistry and a PhD in organic chemistry.
    Related Searches
    • quality
    • Phase I
    • production
    • Clinical Trials
    Suggested For You
    Recipharm Recipharm
    Vetio Animal Health Vetio Animal Health
    Covance Unveils New R&D Center in Shanghai Covance Unveils New R&D Center in Shanghai
    Contracting And Outsourcing Exhibitor List Contracting And Outsourcing Exhibitor List
    Quality Metrics Feedback Quality Metrics Feedback
    Handling & Assessing HPAPIs Handling & Assessing HPAPIs
    Changing the Face of CDMOs Changing the Face of CDMOs
    API to ADC: A Journey Through High Potency API to ADC: A Journey Through High Potency
    Preparing for Your CDMO Selection Process Preparing for Your CDMO Selection Process
    GenCure Reports Successful First Run of 80L Bioreactor GenCure Reports Successful First Run of 80L Bioreactor
    PRA Health Sciences Buys Out Joint Venture in Japan PRA Health Sciences Buys Out Joint Venture in Japan
    FLAMMA Acquires Teva’s Philadelphia cGMP Facility FLAMMA Acquires Teva’s Philadelphia cGMP Facility
    Cytel and Axio Research Merge Cytel and Axio Research Merge
    Speed, Quality and Cost Speed, Quality and Cost
    Vineti Opens New Regional HQ in Maryland Vineti Opens New Regional HQ in Maryland

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • AbbVie Licenses ProBioGen’s GlymaxX Technology
    • CONTINUUS Awarded $69.3M DoD Grant
    Breaking News
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    • AGC Biologics Appoints Boulder Site GM
    • Lilly Completes $1B Acquisition of Prevail
    • Top BioPharma Form Accumulus Synergy
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login